ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

4:00PM-4:50PM: Abstract Number: 0443

Impact of the COVID-19 Pandemic on Racial and Ethnic Minority Groups Diagnosed with Rheumatic Diseases

Healthcare Disparities in Rheumatology (0439–0443)

4:00PM-4:50PM: Abstract Number: 0488

Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database

RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Abstract Number: 0437

Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting

Clinical Practice I (0434–0438)

4:00PM-4:50PM: Abstract Number: 0435

Low Incidence of Coronavirus Disease 2019 (COVID-19) Infection in Patients on Biologic Infusion Therapies at a Community Rheumatology Practice

Clinical Practice I (0434–0438)

4:00PM-4:50PM: Abstract Number: 0485

Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk

RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Abstract Number: 0438

Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Large Private Rheumatology Practice

Clinical Practice I (0434–0438)

4:00PM-4:50PM: Abstract Number: 0484

Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib

RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Abstract Number: 0440

Representation of Women as Authors of Rheumatology Research Articles

Healthcare Disparities in Rheumatology (0439–0443)

4:00PM-4:50PM: Abstract Number: 0436

The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research

Clinical Practice I (0434–0438)

4:00PM-4:50PM: Abstract Number: 0518

The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

4:00PM-4:50PM: Abstract Number: 0517

Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study

Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

4:00PM-4:50PM: Abstract Number: 0441

Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus

Healthcare Disparities in Rheumatology (0439–0443)

5:00PM-5:50PM: Abstract Number: 0496

A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease

SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Abstract Number: 0472

ApoB:ApoA1 Ratio Could Predict Atherosclerotic Risk in Juvenile-SLE Patients Associated with Altered Interferon Signalling in CD8+ T-cells

Pediatric Rheumatology – Basic Science (0469–0473)

5:00PM-5:50PM: Abstract Number: 0464

Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study

Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].